The FDA-approved device tackles venous obstructions with a dual-stent design that includes hybrid and extend stents, according to a June 18 system news release shared with Becker’s. The study that led to its FDA approval enrolled 162 subjects across 30 centers, including Sanger. It found after 12 months, 90.2% of treated veins remained open and unobstructed and that the system had a success rate of 98.7%.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
